Rilzabrutinib shows promising remission rates in IgG4-related disease with minimal glucocorticoid use, offering a safer oral treatment option.
John Stone, MD, MPH
Advertisement
Stone is professor of medicine at Harvard Medical School and the Edward A Fox Chair in Medicine at the Massachusetts General Hospital. He has treated IgG4-related disease (IgG4-RD) since its emergence in recent years and is passionate about educating patients and fellow healthcare providers (HCPs) about the indolent and systemic nature of this disease.
Articles by John Stone, MD, MPH
The introduction of an ICD-10 code specific to IgG4-Related Disease offers a promising opportunity to revolutionize patient care, enable more accurate diagnoses, and improve outcomes.
Advertisement
Latest Updated Articles
Achieving GC-Free IgG4-Related Disease Remission With Rilzabrutinib, with John Stone, MD, MPHPublished: July 9th 2025 | Updated:
New ICD-10 Code is An Important Milestone for Rare Disease PatientsPublished: October 29th 2023 | Updated:
Advertisement
Advertisement